VRCA

+ Watchlist + Portfolio

Verrica Pharmaceuticals Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $4.99
52-Week Range: $3.28 – $9.82
Market Cap: $83.49M
P/E (TTM): —
EPS (TTM): -1.74
Dividend Yield: —

Advanced Metrics

Price/Book: 19.36
PEG Ratio: —
Return on Equity: —
Return on Assets: -43.98%
Gross Margin: 37.68%
Operating Margin: -194.46%
Profit Margin: -102.84%
Current Ratio: 1.45
Debt/Equity: 0.42
Total Debt: $1.81M
Free Cash Flow: $-9.04M
Revenue Growth: -53.90%
Earnings Growth: —
Enterprise Value: $76.33M

VRCA Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$9.03M	$5.12M	$7.57M	$35.58M
Cost of Revenue	$725.00K	$746.00K	$2.74M	$3.44M
Gross Profit	$8.31M	$4.38M	$4.83M	$32.14M
Research & Development	$12.20M	$20.30M	$11.84M	$8.86M
Selling, General & Admin	$17.41M	$47.30M	$58.82M	$35.22M
Operating Expenses	$29.60M	$67.60M	$70.66M	$44.08M
Operating Income	-$21.30M	-$63.22M	-$65.84M	-$11.94M
EBITDA	-$21.60M	-$62.20M	-$65.90M	-$9.36M
Pretax Income	-$24.49M	-$67.00M	-$76.58M	-$17.89M
Net Income	-$24.49M	-$67.00M	-$76.58M	-$17.89M
Diluted EPS	-7.20	-14.80	-14.80	-1.68
Diluted Shares	3.42M	4.53M	5.18M	10.65M

VRCA Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$34.27M	$69.55M	$46.33M	$30.15M
Receivables	$487.00K	$4.42M	$77.00K	$5.40M
Inventory	$0.00	$1.02M	$2.46M	$2.24M
Current Assets	$39.12M	$77.53M	$51.18M	$42.54M
Total Assets	$44.72M	$81.60M	$54.13M	$47.13M
Current Liabilities	$3.46M	$17.02M	$29.01M	$16.44M
Long-Term Debt	—	$42.87M	$30.98M	—
Total Debt	$1.53M	$45.51M	$45.94M	$1.63M
Total Liabilities	$4.69M	$61.83M	$63.99M	$22.39M
Retained Earnings	-$163.45M	-$230.45M	-$307.03M	-$324.91M
Shareholders' Equity	$40.03M	$19.76M	-$9.86M	$24.74M
Working Capital	$35.66M	$60.51M	$22.17M	$26.10M

VRCA Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$18.65M	-$38.58M	-$60.93M	-$17.63M
Capital Expenditure	-$302.00K	-$362.00K	-$27.00K	—
Free Cash Flow	-$18.95M	-$38.94M	-$60.95M	-$17.63M
Depreciation & Amortisation	$718.00K	$836.00K	$1.27M	$781.00K
Stock-Based Compensation	$4.99M	$14.38M	$7.16M	$3.32M
Investing Cash Flow	$54.04M	-$362.00K	-$19.00K	$0.00
Financing Cash Flow	-$16.87M	$74.21M	$37.73M	$1.45M
Net Change in Cash	$18.52M	$35.27M	-$23.22M	-$16.18M

VRCA Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$3.44M	$12.70M	$14.34M	$5.09M	$5.02M
Cost of Revenue	$437.00K	$494.00K	$1.11M	$1.40M	$889.00K
Gross Profit	$3.00M	$12.21M	$13.23M	$3.69M	$4.13M
Research & Development	$2.28M	$1.85M	$2.21M	$2.52M	$3.86M
Selling, General & Admin	$8.85M	$8.85M	$9.40M	$8.12M	$9.99M
Operating Expenses	$11.13M	$10.70M	$11.61M	$10.64M	$13.85M
Operating Income	-$8.13M	$1.51M	$1.63M	-$6.95M	-$9.71M
EBITDA	-$7.33M	$2.53M	$2.00M	-$6.57M	-$9.33M
Pretax Income	-$9.74M	$204.00K	-$274.00K	-$8.07M	-$9.68M
Net Income	-$9.74M	$204.00K	-$274.00K	-$8.07M	-$9.68M
Diluted EPS	-1.00	0.02	-0.03	-0.57	-0.45
Diluted Shares	9.48M	9.49M	9.49M	14.11M	21.31M

VRCA Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$29.59M	$15.40M	$21.10M	$30.15M	$20.60M
Receivables	$5.65M	$17.37M	$7.33M	$5.40M	$7.81M
Inventory	$2.46M	$2.52M	$2.30M	$2.24M	$1.97M
Current Assets	$39.47M	$36.78M	$36.27M	$42.54M	$34.13M
Total Assets	$42.18M	$39.11M	$40.90M	$47.13M	$38.79M
Current Liabilities	$29.40M	$29.22M	$28.91M	$16.44M	$16.22M
Long-Term Debt	$27.81M	$24.58M	$21.62M	—	—
Total Debt	$42.43M	$38.89M	$35.74M	$1.63M	$1.44M
Total Liabilities	$60.75M	$56.59M	$57.94M	$22.39M	$22.73M
Retained Earnings	-$316.77M	-$316.56M	-$316.84M	-$324.91M	-$334.60M
Shareholders' Equity	-$18.58M	-$17.48M	-$17.04M	$24.74M	$16.05M
Working Capital	$10.08M	$7.56M	$7.37M	$26.10M	$17.91M
Net Debt	$11.04M	$21.86M	$12.98M	—	—

VRCA Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$12.68M	-$10.04M	$9.69M	-$4.59M	-$9.16M
Free Cash Flow	-$12.68M	-$10.04M	$9.69M	-$4.59M	-$9.16M
Depreciation & Amortisation	$208.00K	$199.00K	$184.00K	$190.00K	$194.00K
Stock-Based Compensation	$1.03M	$888.00K	$718.00K	$686.00K	$897.00K
Investing Cash Flow	$0.00	$0.00	$0.00	$0.00	$0.00
Financing Cash Flow	-$4.06M	-$4.16M	-$3.98M	$13.64M	-$120.00K
Net Change in Cash	-$16.73M	-$14.20M	$5.70M	$9.05M	-$9.28M

Market Snapshot

About

Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing medications for skin diseases requiring medical intervention. The company focuses on developing and commercializing treatments for dermatological conditions with significant unmet medical needs. Verrica's lead product candidate targets common warts and molluscum contagiosum.